早期预后不良类风湿关节炎患者接受阿巴西普治疗后转为血清阴性状态与更好的影像学结局和持续缓解相关:AGREE 研究的事后分析
AGREE 研究的事后分析纳入未使用甲氨蝶呤的早期预后不良类风湿关节炎患者,比较阿巴西普联合甲氨蝶呤与安慰剂联合甲氨蝶呤。阿巴西普联合甲氨蝶呤与抗环瓜氨酸蛋白抗体(ACPA)滴度下降更大及 ACPA 和类风湿因子(RF)血清阴性转化率更高相关,ACPA 血清阴性转化与更好的临床和影像学结局相关。
要点
- 阿巴西普联合甲氨蝶呤较单用甲氨蝶呤更易诱导早期侵蚀性类风湿关节炎患者 ACPA/RF 血清阴性转化。
- 阿巴西普联合甲氨蝶呤组中转为 ACPA 血清阴性的患者达到缓解的比例高于持续 ACPA 阳性者。
- 阿巴西普联合甲氨蝶呤组中转为 ACPA 血清阴性的患者持续缓解概率更高且影像学进展更少。
核心结论
- 阿巴西普联合甲氨蝶呤更可能诱导早期侵蚀性类风湿关节炎患者转为 ACPA/RF 血清阴性状态。
- 转为 ACPA 血清阴性状态与更好的临床和影像学结局相关。
研究设计与样本
- AGREE 研究的事后分析,III 期研究,纳入未使用甲氨蝶呤的早期类风湿关节炎且预后不良因素患者。
- 患者随机接受阿巴西普(约 10 mg/kg 静脉注射,按体重范围)或安慰剂,联合甲氨蝶呤治疗 12 个月,随后开放标签阿巴西普联合甲氨蝶呤治疗 12 个月。
- 基线及第 6、12 个月(双盲期)通过 ELISA 测定自身抗体滴度,评估第 6 和 12 个月血清阴性转化及其与临床反应的关系。
主要发现
- 阿巴西普联合甲氨蝶呤与 ACPA(而非 RF)滴度下降更大相关,且 ACPA 和 RF 血清阴性转化率均高于单用甲氨蝶呤。
- 接受阿巴西普联合甲氨蝶呤并转为 ACPA 血清阴性的患者中,达到基于 28 关节疾病活动评分(C 反应蛋白)或临床疾病活动指数缓解的比例高于持续 ACPA 血清阳性者。
- 接受阿巴西普联合甲氨蝶呤并转为 ACPA 血清阴性的患者,达到持续缓解的概率更高且影像学进展更少,优于单用甲氨蝶呤或持续 ACPA 血清阳性者(无论何种治疗)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effects of the T-cell costimulation blocker abatacept on anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) in early rheumatoid arthritis (RA), and associations between changes in serological status and clinical response. METHODS: Post hoc analysis of the phase III AGREE study in methotrexate (MTX)-naïve patients with early RA and poor prognostic factors. Patients were randomised to abatacept (~10 mg/kg intravenously according to weight range) or placebo, plus MTX over 12 months followed by open-label abatacept plus MTX for 12 months. Autoantibody titres were determined by ELISA at baseline and months 6 and 12 (double-blind phase). Conversion to seronegative status and its association with clinical response were assessed at months 6 and 12. RESULTS: Abatacept plus MTX was associated with a greater decrease in ACPA (but not RF) titres and higher rates of both ACPA and RF conversion to seronegative status versus MTX alone. More patients converting to ACPA seronegative status receiving abatacept plus MTX achieved remission according to Disease Activity Score in 28 joints (C-reactive protein) or Clinical Disease Activity Index than patients who remained ACPA seropositive. Patients who converted to ACPA seronegative status treated with abatacept plus MTX had a greater probability of achieving sustained remission and less radiographic progression than MTX alone or patients who remained ACPA seropositive (either treatment). CONCLUSIONS: Treatment with abatacept plus MTX was more likely to induce conversion to ACPA/RF seronegative status in patients with early, erosive RA. Conversion to ACPA seronegative status was associated with better clinical and radiographic outcomes. TRIAL REGISTRATION NUMBER: NCT00122382.
引用
- Jansen DTSL, Emery P, Smolen JS, et al. Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. RMD Open. 2018. PMID: 29657830. doi:10.1136/rmdopen-2017-000564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。